ClinicaliQ Trial Snapshot
- DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations — Recruiting • Phase II • Oncology • NCT05786716.
- What is being tested: The efficacy and safety of combined trastuzumab and pertuzumab (two HER2-targeted monoclonal antibodies) across multiple cancer types with HER2 amplification or activating mutations in adult, paediatric, and teenage/young adult patient populations.
- Patient eligibility overview: Adults, teenagers, and children with HER2-amplified or HER2-mutated cancers are eligible; whilst this combination is established standard care for adult HER2-positive breast cancer, this trial extends evaluation to other cancer types and younger age groups who currently lack evidence-based….
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other anti-cancer drugs). This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Trastuzumab and pertuzumab work in patients with these types of cancers which have a molecular alteration called HER2 amplification or HER2 activating mutation. Investigators now wish to find out if…
Eligibility Snapshot
- THE PATIENT MUST FULFIL THE ELIGIBILITY CRITERIA WITHIN THE DETERMINE MASTER PROTOCOL (NCT05722886) AND WITHIN THE TREATMENT ARM 04 (TRASTUZUMAB AND PERTUZUMAB) OUTLINED BELOW* *When trastuzumab- and pertuzumab-specific inclusion/
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.